Inhibición de la tirosina cinasa esplénica en el tratamiento de la artritis reumatoide
Rheumatology 2013;52:1556–1562 doi:10.1093/rheumatology/ket225
Both the innate and adaptive immune responses are targeted by current RA treatments, but these treatments do not achieve consistent sustained disease remission. Protein kinase inhibitors represent a promising new therapeutic target, owing to their influence on downstream signalling and oral bioavailability. Fostamatinib (R788) has shown ACR20 responses of 67–72% in MTX inadequate responder patients at doses of 100mg bd and 150mg bd. However, the results in biologic non-responder patients were no...